anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
PURPOSE: A dye composition containing Citrus grandis extract for treating atopic dermatitis is provided to minimize side effect using natural product. CONSTITUTION: A dye composition for treating atopic dermatitis contains Citrus grandis extract as an active ingredient. A fiber is dyed by contacting the dye composition to the fiber. The fiber is natural fiber, artificial fiber or blend fiber. The fiber is cotton, wool, silk, acetate, triacetate, nylon, polyvinyl alcohol(PVA), polyester, polyacryl, polyamide, polyurethane, polyacrylonitrile or blend fiber thereof. A fiber product having activity of treating atopic dermatitis is dyed with the composition. The fiber product is manufactured in the form of shirts, socks, underwear, diaper, blanket, pillow, patch agent, bandage, couch or chair.
The invention mainly aims at providing a natural non-toxic mosquito repellent and skin care agent. The natural non-toxic mosquito repellent and skin care agent consists of the following components and contents by the parts by weight: 0.5 to 5 portions of spearmint essential oil, 2 to 10 portions of glycerol, 0.5 to 4 portions of Twenn-80 and the rest of deionized water. The natural non-toxic mosquito repellent and skin care agent is characterized in that the composition consists of the following components and contents by the portions by weight: 0.5 to 5 portions of spearmint essential oil, 0.5 to 7 portions of emulsifier, 2 to 10 portions of glycerol, 0 to 0.3 portions of triethanolamine, 0 to 1 portion of carbopol and the rest of deionized water. The invention takes the spearmint essential oil as the crude drug, the dosage is less than five percent, and then the emulsifier and glycerol etc. are added for preparation. The invention has good mosquito repellent effect and is natural and non-toxic; furthermore, the invention has the skin care function; the invention has no greasy sense, cool skin sense and a plurality of effects of mosquito repellent, anti-inflammatory, anti-allergic and refreshing after the usage, so the invention is especially suitable for the infants for usage.
The inclusion criteria were to be between 18-65 years of age, to be willing to participate in the study, to have no problems in reading and/or understanding the scales and to be able to cooperate with the tests. Exclusion criteria were having any orthopedic or neuromuscular condition that would interfere with walking or exercise performance, having any chronic disease, or having psychiatric disorders or mental disorders that might interfere with cooperation or compliance with exercise tests.
OBJECTIVE: To explore the effects of comprehensive nursing combined with thermal insulation measures on the awakening agitation (EA) of cesarean section parturient under general anesthesia and maternal and infant safety.
METHODS: A total of 136 cesarean section parturients under general anesthesia admitted in our hospital from May 2020 to November 2023 were picked as the research objects following the random, double-blind method. All patients have no mental illness and can clearly reflect their physical state. The subjects were randomized into the study group and the control group in accordance with the random number table method, with 68 cases in each group. The control group was intervened with thermal insulation measures, while the study group was intervened with comprehensive nursing combined with thermal insulation measures. Systolic blood pressure (SBP), diastolic blood pressure (DBP), mean arterial pressure (MAP), and heart rate (HR) at different time points were compared. The Ramsay score (RASS), the incidence of EA, and the incidence of shivering were compared. The influence of comprehensive nursing combined with thermal insulation measures on maternal and infant safety and their recovery after the operation was analyzed. The adverse psychological status and postoperative satisfaction of the two groups were statistically analyzed.
RESULTS: SBP, DBP, and MAP in the study group were much higher than those in the control group at the time of skin incision, fetal delivery, and the end of operation (P < .05). Compared with the control group, the study group had much higher RASS, and sharply reduced incidence of EA and shivering (P < .05). The incidence of fetal distress, postpartum hemorrhage, neonatal asphyxia, etc., was significantly lower in the study group than in the control group P < .05). Parturient of the study group had a shorter duration of hospitalization, shorter detention time in the anesthesia monitoring room, and awakening time than the parturient in the control group (P < .05). The SAS and SDS scores of parturient were significantly decreased in the two groups at discharge than before the operation, and a more obvious decrease was found in the study group (P < .01). Postoperative satisfaction of the study group and the control group was 98.53% and 80.88%, respectively, which was markedly higher in the study group than in the control group (P < .05).
CONCLUSION: Comprehensive nursing combined with thermal insulation measures vastly improved the sedation degree of parturient, reduced the incidence of EA and chills, ensured maternal and infant safety, reduced adverse pregnancy outcomes, promoted early recovery of parturient, and enhanced maternal satisfaction. This conclusion provides important guidance for improving clinical practice, emphasizing the key role of comprehensive care in improving surgical outcomes and patient comfort, thereby improving the quality and efficiency of medical services.
The high recurrence rate of odontogenic keratocysts (OKC) entails a large number of follow-up interventions after primary surgery. This study aimed to compare recurrent with primary OKC in regard to recurrence rate, treatment modality, radiographic and clinical findings. A single center retrospective cohort study with surgically treated OKC between 2012 and 2021 was conducted. The primary predictor was recurrence type of the lesion: primary (P-OKC), first recurrence (R1-OKC) and second recurrence (R2-OKC). The primary outcome variables were recurrence and time to recurrence. 68 surgeries were identified. Recurrence was not significantly associated with recurrence type (p = 0.906) but with the method of surgery (p < 0.001). Marsupialized R1-OKC recurred earlier than marsupialized P-OKC. Diameter was significantly associated with recurrence type (p = 0.002). R1-OKC had a smaller median diameter than P-OKC and R2-OKC were smaller than R1-and P-OKC. P-OKC were associated with teeth in 79% of surgeries, R1-OKC in 61% and R2-OKC in 27% (p = 0.007). Postoperative numbness was present after 40% of surgeries and decreased to 15% at follow-up, independently of recurrence type. Time to recurrence may be shorter for recurrent marsupialized OKC. Recurrent OKC are smaller and less often associated with teeth. Postoperative numbness after OKC surgery has a good prognosis.
Participants will receive adebrelimab plus carboplatin /cisplatin and etoposide during the induction phase (4-6 cycles of three weeks.). Thereafter, participants will receive maintenance (after induction phase) adebrelimab plus apatinib until persistent PD, intolerable toxicity or withdrawal of consent.
The processes involved in regeneration of cutaneous compared to corneal tissues involve different intrinsic mechanisms. Importantly, cutaneous wounds involve healing by angiogenesis but vascularization of the cornea obscures vision. Previous studies showed that topically applied calreticulin (CALR) healed full-thickness excisional animal wounds by a tissue regenerative process markedly enhancing repair without evoking angiogenesis. In the current study, the application of CALR in a rabbit corneal injury model: (1) accelerated full wound closure by 3 days (2) accelerated delayed healing caused by corticosteroids, routinely used to prevent post-injury inflammation, by 6 days and (3) healed wounds without vascularization or fibrosis/hazing. In vitro, CALR stimulated proliferation of human corneal epithelial cells (CE) and corneal stromal cells (keratocytes) by 1.5-fold and 1.4-fold, respectively and induced migration of CE cells and keratocytes, by 72% and 85% compared to controls of 44% and 59%, respectively. As a marker of decreased fibrosis, CALR treated corneal wounds showed decreased immunostaining for α-smooth muscle actin (α-SMA) by keratocytes and following CALR treatment in vitro, decreased the levels of TGF-β2 in human CE cells and α-SMA in keratocytes. CALR has the potential to be a novel therapeutic both, to accelerate corneal healing from various injuries and in conjunction with corticosteroids.
FIELD: beekeeping. SUBSTANCE: invention relates to processing beeswax to produce perfumery and cosmetic raw materials. Starting material, in particular divided wax or a waxed material, is subjected to two-step extraction. In the first step, extraction is accomplished with liquefied carbon dioxide for 2-4 h at 22-26 C and pressure 6.0-7.0 MPa. Resulting carbon dioxide extract is then treated with 94% ethanol for 5-10 min at 20-25 C giving alcohol-soluble and alcohol-insoluble portions. EFFECT: improved environmental safety of process and enabled isolation of well dispersible preparations. 2 ex
Do not insert any part of the aerosol container directly into the anus. Contents of the container are under pressure. Do not burn or puncture the aerosol container. Do not store at temperatures above 120°F. Because Cortifoam® is not expelled, systemic hydrocortisone absorption may be greater from Cortifoam® than from corticosteroid enema formulations. If there is not evidence of clinical or proctologic improvement within two or three weeks after starting Cortifoam® therapy, or if the patient's condition worsens, discontinue the drug.

Rare instances of anaphylactoid reactions have occurred in patients receiving corticosteroid therapy (see ADVERSE REACTIONS).
Iodine is essential for the synthesis of thyroid hormones, and thyroid hormones regulate the metabolic processes of most cells and play important roles in human growth and development. Iodine deficiency disorders can have serious consequences on brain and physical development. In neonates iodine deficiency and hence insufficient supply of thyroid hormones could cause neonatal goiter, neonatal hypothyroidism, and endemic mental retardation.

Iodine deficiency disorders can be prevented and controlled by providing iodine and iodine can be provided in different ways. However, the United Nations Children's Fund and the World Health Organization jointly recommended salt iodization where iodized salt is accessible. Iodized salt is a safe, cost effective and sustainable strategy to ensure sufficient intake of iodine by all individuals and to improve maternal and infant health. However, although the effect of iodine on human health is well established efficacy of iodized salt has not been studied.
Mechanisms are provided for automatically annotating input images with bounding region annotations and corresponding anomaly labels. The mechanisms segment an input image to generate a mask corresponding to recognized internal structures of a subject. A template data structure is generated that specifies standardized internal structure zones of the subject. The mechanisms register the mask with the template data structure to generate a template registered mask identifying standardized internal structure zones present within the mask, and generate bounding region annotations for each standardized internal structure zone of the template registered mask. The bounding region annotations are correlated with labels indicating whether or not the bounding region comprises an anomaly in the input image based on an analysis of a received natural language text description of the input image. The bounding region annotations and labels are stored in association with the input image.
The invention provides a segment of shRNA sequence: GCTGGTCTGACTCACATAATG, annealing the sequence, inserting siRNA expression plasmid, and transforming Escherichia coli. Positive clones are screened by cloning PCR, and strains are reserved. Amplifying the gene engineering bacteria, and extracting and purifying plasmids. The plasmid was transfected into MDCK cells. Then the cells are infected by influenza virus, after 48 hours, cell culture supernatant is collected, total RNA is extracted, and the content of the influenza virus in the culture supernatant is detected by an RT-PCT method. BALB/C mice were given nebulized inhalation as a complex of the plasmid with PEI for 3 consecutive days for 30 minutes per day. The mice were then challenged with influenza virus and sacrificed 3 days later. Taking out the lung to prepare tissue homogenate, extracting total RNA from the tissue homogenate, and detecting the content of influenza virus in culture supernatant by an RT-PCT method. The shRNA can be determined to have the function of inhibiting the replication of influenza viruses according to the content of different groups of influenza viruses.
Stroke is one of the most common causes of mortality and disability worldwide. Antithrombotic therapy represents the mainstay in primary and secondary prevention, both in cardioembolic and non-cardioembolic stroke. Particularly, direct oral anticoagulants play a crucial role in atrial fibrillation, the most common cause of cardioembolic stroke, whereas single or dual antiplatelet therapy is preferred in non-cardioembolic stroke. However, the limitations related to the residual risk of cardioembolic or cerebrovascular events, and the risk of major bleeding, still represent unmet medical needs. To overcome them, new drugs inhibiting Factor XI (FXI) and Factor XII have been proposed, with a selective inhibition of contact pathway of coagulation, delineating a new anticoagulant approach. This review provides a summary of the currently available evidence and future perspectives on FXI inhibitors, that can represent an additional therapeutic option in the primary and secondary prevention of cardioembolic and non-cardioembolic ischemic stroke, also in challenging therapeutic contexts.
Participants will follow their regular diet for two weeks before 3-day lead-in food prior to the metabolic testing at visit 0. Participants will then be instructed to eat their habitual diet only within a 10-hour time frame each day for 8 weeks. Participants may self-select the precise window that best suits their lifestyles, however any food and drink must be consumed by 7:30pm.
PURPOSE:The titled agent, containing a specific dipeptide derivative as an active constituent and useful as an anti-infective agent and immunological activator without side effect. CONSTITUTION:An anti-infective agent and immunological activator containing a dipeptide derivative expressed by the X-Y and cyclo(-X-Y-) (X is tyrosine, phenylalanine, tryptophan or D-type isomer thereof; Y is arginine or D-type isomer thereof) as an active constituent. The above-mentioned dipeptide derivative has improved characteristics as an anti-infective agent having immunological activating action and immunological activator without exhibiting side effect, e.g. peptidase inhibitory action as bestatin. The above-mentioned anti-infective agent and immunological activator are formulated into injection, tablet, powder, etc., by the conventional method and administered by intravenous injection, oral administration, etc. The effective dose thereof is 10-100mg per kg body weight.
BACKGROUND: Intermittent fasting (IF) is an effective energy restricted dietary strategy to reduce body and fat mass and improve metabolic health in individuals with either an overweight or obese status. However, dietary energy restriction may impair muscle protein synthesis (MPS) resulting in a concomitant decline in lean body mass. Due to periods of prolonged fasting combined with irregular meal intake, we hypothesised that IF would reduce rates of MPS compared to an energy balanced diet with regular meal patterns.
AIMS: We assessed the impact of a short-term, ten days, alternate day fasting or a continuous energy restricted diet to a control diet on integrated rates of skeletal MPS in middle-aged males with overweight or obesity.
METHODS: Twenty-seven middle-aged males with overweight or obesity (age: 44.6 ± 5.4 y; BMI: 30.3 ± 2.6 kg/m2) consumed a three-day lead-in diet, followed by a ten-day controlled dietary intervention matched for protein intake, as alternate day fasting (ADF: 62.5 energy (En)%, days of 25 En% alternated with days of 100 En% food ingestion), continuous energy restriction (CER: 62.5 En%), or an energy balanced, control diet (CON: 100 En%). Deuterated water (D2O) methodology with saliva, blood, and skeletal muscle sampling were used to assess integrated rates of MPS over the ten-day intervention period. Secondary measures included fasting plasma glucose, insulin, and gastrointestinal hormone concentrations, continuous glucose monitoring, and assessment of body composition.
RESULTS: There were no differences in daily rates of MPS between groups (ADF: 1.18 ± 0.13, CER: 1.13 ± 0.16, and CON: 1.18 ± 0.18 %/day, P > 0.05). The reductions in body mass were greater in ADF and CER compared to CON (P < 0.001). Lean and fat mass were decreased by a similar magnitude across groups (main time effect, P < 0.001; main group effect, P > 0.05). Fasting plasma leptin concentrations decreased in ADF and CER (P < 0.001), with no differences in fasting plasma glucose or insulin concentrations between groups.
CONCLUSION: Short-term alternate day fasting does not lower rates of MPS compared to continuous energy restriction or an energy balanced, control diet with matched protein intake. The prolonged effects of IF and periods of irregular energy and protein intake patterns on muscle mass maintenance remain to be investigated. This trial was registered under Australian New Zealand Clinical Trial Registry (https://www.anzctr.org.au), identifier no. ACTRN12619000757112.
The present invention relates to purified preparations of a novel retrovirus, to methods of diagnosis and treatment of Sjogren's syndrome, novel cell lines, and model systems for the study of autoimmune diseases and AIDS. It is based, in part, on the discovery of a novel retrovirus which is antigenically similar to human immunodeficiency virus but which appears to comprise a functionally distinct reverse transcriptase. According to the present invention, Sjogren's syndrome as well as other autoimmune diseases, may be diagnosed, and their clinical course may be monitored, by demonstrating the presence of anti-retroviral antibodies and/or measuring the levels of such antibodies. Alternatively, Sjogren's syndrome or other autoimmune diseases may be diagnosed or monitored by directly or indirectly demonstrating viral particles in the cells of a patient. Furthermore, according to the invention, Sjogren's patients who have been found to exhibit retrovirus or anti-retroviral antibodies may be treated with agents known to be useful in the treatment of retroviral diseases, including but not limited to, agents which interfere with reverse transcriptase function, such as, for example, nucleoside analogues (e.g. zidovudine or dideoxyinosine).
The invention relates to a blood purification concentrate, belonging to the technical field of medical instruments. The invention overcomes the defects of the prior art, solves the defects of the acid-base regulator in the common purification concentrate at present, and the acid-base regulator used in the invention is physiologically necessary acid. The blood purification concentrate is a solid or liquid preparation, and the contained pH regulator is a mixture of one or two or three of fumaric acid or maleic acid and succinic acid and citric acid. The mixture is used as an acid-base regulator, and the calcium ions, the magnesium ions and the carbonate ions are effectively prevented from being combined to generate precipitates. A stable dialysis solution was formed. Preventing blood coagulation and achieving safe treatment effect. The invention is acetic acid-free blood purification concentrate, and completely overcomes the complications caused by acetate in the treatment process of the traditional dialysate. The pH regulator of the present invention is an important substance in the tricarboxylic acid cycle, and plays an important buffering role in preventing acidosis.
Patients receive goserelin acetate, leuprolide acetate, or triptorelin via injection every 3 months for 12 months (4 injections), every 4 months for 12 months (3 injections), or every month for 12 months (12 injections) in the absence of disease progression or unacceptable toxicity. Patients also receive a placebo four times daily (QID) for 52 weeks in the absence of disease progression or unacceptable toxicity.
Melanoma is a serious form of skin cancer. If untreated, the melanoma can spread beyond the original affected tissue and invade distant tissue and organs. Treatment for metastatic melanoma includes medical treatments (chemotherapy or immunotherapy), surgery, or radiation therapy. MORAb-028 is a recombinant human immunoglobulin M (IgM) monoclonal antibody that recognizes a cell surface diacyl ganglioside named disialoganglioside (GD2). GD2 is overexpressed in tumors of neuro-ectodermal origin such as melanomas, neuroblastomas, small-cell lung carcinomas, and many sarcomas, while absent in most normal tissues. GD2 expression has been demonstrated in human melanoma and small cell lung cancer by thin layer chromatography and radiolabeled anti-GD2 antibody detection. It is hypothesized that one mode of action of MORAb-028 is complement-dependent cytotoxicity. Complement-dependent cytotoxicity is a mechanism for killing tumor cells in which an antibody bound to the target cell surface fixes complement, which results in assembly of the complement membrane attack complex that punches holes in the target cell membrane resulting in subsequent cell lysis. IgMs strongly bind to C1Q and robustly activate complement-dependent cytotoxicity. MORAb-028 is being developed as a potential therapy for GD2-positive tumors.
Narafilcon A randomly assigned to one eye, with delefilcon A assigned to the fellow eye for contralateral wear. Both products will be worn for one day for 16 hours (+/- 1 hour).
High-dose intravenous cyclophosphamide 1,000 mg/m2/dose, the first dose will be started with 500 mg/m2/dose and steped up to 750 mg/m2/dose for the second dose. Then the dosage will be increased to 1,000 mg/m2/dose for the third dose and continued the dosage through the seventh dose. Total duration is 6 months for the induction treatment.